EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network

Arnaud Jannin iD, Fabiola Giudici, Christelle de la Fouchardière, Abir Al Ghuzlan, Johanna Wassermann, Cecile N Chougnet, Delphine Drui, Yann Godbert, Frédéric Ilouz, Stéphane Bardet, Sylvie Zanetta, Nathalie Roudaut und 13 weitere

Thyroid® · 2023

DOI: 10.1089/thy.2023.0164 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thyroid®, 2023. Verfasst von Arnaud Jannin und 24 weiteren Autor:innen. Beteiligte Einrichtung: CHU Lille, Department of Endocrinology, Diabetology, and Metabolism, Lille, France. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This study evaluated the factors associated with overall survival (OS) of patients with ATC using multicenter real-world data from a national tertiary care center network in France.

Methods

In this multicenter, retrospective cohort study, all patients with ATC diagnosed between 2010 and 2020 were identified from the national database of the French ENDOCAN-TUTHYREF network. Factors associated with OS were examined in multivariable analyses using Cox proportional hazards models.

Results

The study included 360 patients. Of these, 220 (61%) were female and the median age was 72 years (interquartile range: 62–80). The percentages of patients with pure and mixed (synchronously-transformed) ATC (p-ATC and st-ATC) were 62.5% and 26.7%, respectively. The median OS was 6.8 months [confidence interval, CI: 5.5–8.1]: not reached for stage IVa, 11.4 months [8.2–17.8] for IVb, and 4.6 months [3.5–5.7] for IVc. Surgery, radiation therapy to the neck, chemotherapy, and best supportive care were administered to 69 (19.2%), 214 (59.4%), 254 (70.6%), and 66 (18.3%) patients, respectively. In a multivariable analysis, including stage IVb–IVc patients, significantly higher OS was observed in patients with Eastern Cooperative Oncology Group performance-status of 0–1 (hazard ratio [HR], 0.6; [CI, 0.4–0.9], p < 0.02), stage IVb [HR, 0.5; CI, 0.4–0.8, p < 0.001], and multimodal treatment (surgery and chemoradiotherapy) [HR, 0.07; CI, 0.04–0.1, p < 0.001]. Variables associated with significantly worse OS included: p-ATC (vs. st-ATC) [HR, 1.83; CI, 1.33–2.51, p = 0.001] and a neutrophil-to-lymphocyte ratio (NLR) >5.05 [HR, 2.05, CI, 1.39–3.05, p < 0.001].

Conclusions

Factors independently associated with improved OS in ATC included: European Cooperative Oncology Group performance status, disease stage, multimodality treatment, synchronously transformed ATC, and lower NLR. Long-term OS was observed in selected patients with ATC who underwent multimodal treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsHumansFemaleAgedMaleRetrospective StudiesThyroidectomyCombined Modality TherapyPrognosis

Stichwörter der Autor:innen

anaplastic thyroid carcinomaneutrophil-to-lymphocyte ratiooverall survivalprognosistargeted therapy

Autor:innen und Institutionen

  • CHU Lille, Department of Endocrinology, Diabetology, and Metabolism, Lille, France.
  • Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer-Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
  • Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
  • Oncostat, U1018, CESP, Inserm, Paris-Saclay University, "Ligue Contre le Cancer" labeled team, Villejuif, France.
  • Medical Oncology Department, Centre Léon Bérard/Research Center of Lyon (CRCL), UMR INSERM 1052, Lyon, France.
  • Department of Biology and Pathology, Gustave Roussy Cancer Campus and University Paris-Saclay, Villejuif, France.

ORCID-Profile: Arnaud Jannin, Christine Do Cao, Julien Hadoux

Zitieren

APA

Jannin, A., Giudici, F., de la Fouchardière, C., Al Ghuzlan, A., Wassermann, J., Chougnet, C. N., Drui, D., Godbert, Y., Ilouz, F., Bardet, S., Zanetta, S., Roudaut, N., Batisse Lignier, M., Groussin, L., Klein, M., Zerdoud, S., Lamartina, L., Baudin, E., Decaussin-Petrucci, M., …, & ENDOCAN-TUTHYREF Network (2023). Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network. Thyroid®. https://doi.org/10.1089/thy.2023.0164

Vancouver

Jannin A, Giudici F, de la Fouchardière C, Al Ghuzlan A, Wassermann J, Chougnet CN, et al. Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network. Thyroid®. 2023. doi:10.1089/thy.2023.0164

BibTeX
@article{Jannin2023,
  author = {Jannin, Arnaud and Giudici, Fabiola and de la Fouchardière, Christelle and Al Ghuzlan, Abir and Wassermann, Johanna and Chougnet, Cecile N and Drui, Delphine and Godbert, Yann and Ilouz, Frédéric and Bardet, Stéphane and Zanetta, Sylvie and Roudaut, Nathalie and Batisse Lignier, Marie and Groussin, Lionel and Klein, Marc and Zerdoud, Slimane and Lamartina, Livia and Baudin, Eric and Decaussin-Petrucci, Myriam and Leteurtre, Emmanuelle and Borson Chazot, Francoise and Do Cao, Christine and Borget, Isabelle and Hadoux, Julien and ENDOCAN-TUTHYREF Network, ENDOCAN-TUTHYREF Network},
  title = {Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network},
  journal = {Thyroid®},
  year = {2023},
  doi = {10.1089/thy.2023.0164}
}
Kostenlos starten →